Randomized, Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Subcutaneous Beloranib in Suspension) in Obese Subjects With Prader-Willi Syndrome to Evaluate Total Body Weight, Food-related Behavior, and Safety Over 6 Months

Trial Profile

Randomized, Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Subcutaneous Beloranib in Suspension) in Obese Subjects With Prader-Willi Syndrome to Evaluate Total Body Weight, Food-related Behavior, and Safety Over 6 Months

Suspended
Phase of Trial: Phase III

Latest Information Update: 20 Dec 2016

At a glance

  • Drugs Beloranib (Primary)
  • Indications Prader-Willi syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms bestPWS
  • Sponsors Zafgen
  • Most Recent Events

    • 10 May 2016 According to a Zafgen media release, data from this trial was presented at the XIII International Congress on Obesity (ICO).
    • 04 Apr 2016 Results presented at The 98th Annual Meeting of the Endocrine Society
    • 04 Apr 2016 Results of improvement in lipid profile and cardiometabolic biomarker presented at The 98th Annual Meeting of the Endocrine Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top